Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
A systematic review of matched cohort and case-control studies was performed to examine the mortality attributable to candidemia. The review included studies that compared mortality of patients with candidemia (cases) to that of matched patients without candidemia (controls). Secondary variables examined were the length and cost of hospital stay. Relevant studies were identified using the PubMed database and by examining the references of the initially selected studies. Two independent reviewers performed the literature search, study selection and data extraction from the identified studies. A total of seven studies were included in the review. The patients included those hospitalized in intensive care units (ICU) and hospital wards and those undergoing transplantation. The mortality attributed to candidemia in the reviewed studies ranged from 5 to 71%. For six of the reviewed studies the difference in mortality between cases and controls was statistically significant. Among those who survived, the length of stay and the cost of hospitalization of patients with candidemia were significantly higher than those of controls. Despite the methodological heterogeneity of the reviewed studies, the data from the available matched cohort and case-control studies suggest that candidemia is associated with considerable mortality that is attributed, at least to some degree, to the infection itself and not only to the presence of another comorbidity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estimates of mortality attributable to candidemia range from 5% to 71%, varying based on setting, age group, and study design [10].”
From Burden of Candidemia in the United States, 2017 (2020) · cites this paper as [10]
In the citing paper
“The mortality attributed to candidemia, in the reviewed studies, ranged from 5 to 71%, and for six, the difference in mortality between cases and controls was statistically significant.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [14]
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 1×
“It should be noted, as also stated by the authors of the study, that this definition is not in accordance with the Infectious Diseases Society of America (IDSA) guidelines for treatment of candidiasis [19]; these consider treatment for candidemia adequate if amphotericin B, fluconazole or caspofungin continues for 2 w…”
ResultNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 1×
“This is also stressed in other articles [17, 18].”
ResultSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 8×
“It is also interesting that when the results were analyzed using matched-pair analysis, the difference between cases and controls in the median number of days spent in hospital was further augmented [12, 13].”
BackgroundResultInfluential(1999) · American Journal of Infection Control · doi:10.1016/s0196-6553(99)70031-3 · Cited by 901
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831 · cited 8×
“[13] performed matching according to disease severity.”
BackgroundResultInfluentialZaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784 · cited 7×
“length of hospital stay of adult cases was more than double that of controls [10].”
BackgroundMethodResultInfluential
Cited by
-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Karageorgopoulos, D. E., Vouloumanou, E. K., Ntziora, F., Michalopoulos, A., Rafailidis, P. I., & Falagas, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq206 · Cited by 538
“mortality rate associated with IFIs is considerably high [7].”
BackgroundSelf-citationPfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
“In the present series, survival appeared to have improved, compared with that in many older studies (Falagas et al., 2006; Gudlaugsson et al., 2003; Wey et al., 1988; Zaoutis et al., 2005).”
ResultKett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c1ca · Cited by 389
“1%, respectively) and longer intensive care unit lengths of stay (median [interquartile range]) (33 days [18–44], 20 days [9–43], and 21 days [8–46], respectively); however, these differences were not statistically significant.”
BackgroundInvasive candidiasis as a cause of sepsis in the critically ill patient
Delaloye, J., & Calandra, T. (2014) · Virulence · doi:10.4161/viru.26187 · Cited by 372
“The attributable mortality of invasive candidiasis was reported to be somewhere between 5% and 71%.(16,19,20) This wide range probably reflects the inherent difficulty of assessing whether these critically ill patients died either with or from fungal infections.”
BackgroundFalagas, M. E., Roussos, N., & Vardakas, K. Z. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.04.006 · Cited by 346
Self-citationNosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention
Alangaden, G. J. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.11.003 · Cited by 337
“Matched cohort and case-control studies in various hospitalized patient populations, including those in the ICU and those who have undergone a transplant, report attributable mortality rates for candidemia ranging from 5% to 71%.(15) A recent case-control study based on hospital discharge diagnosis estimated the morta…”
McCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285
Recent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
“Bloodstream infections are associated with considerable attributable mortality rates varying from 30 to 70 % (Bouza et al. 2013; Falagas et al. 2006; Kibbler et al. 2003; Peng and Lu 2013; Wey et al. 1988; Wisplinghoff et al. 2004) and high healthcare costs with estimates ranging from millions to 1…”
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01079-10 · Cited by 238
Potential Use of Phenolic Acids as Anti-Candida Agents: A Review
Teodoro, G. R., Ellepola, K., Seneviratne, C. J., & Koga-Ito, C. Y. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01420 · Cited by 204
“It significantly increases the period of hospitalization, economic burden and mortality, especially in ICU patients or those under chemotherapy or with a history of abdominal surgery (Falagas et al., 2006; Berdal et al., 2014; Drgona et al., 2014).”
BackgroundDimopoulos, G., Ntziora, F., Rachiotis, G., Armaganidis, A., & Falagas, M. E. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181607262 · Cited by 189
Self-citationIntensive care medicine research agenda on invasive fungal infection in critically ill patients
Bassetti, M., Garnacho-Montero, J., Calandra, T., Kullberg, B., Dimopoulos, G., Azoulay, E., Chakrabarti, A., Kett, D., Leon, C., Ostrosky-Zeichner, L., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4731-2 · Cited by 183
“Assessing the attributable mortality of IC is difficult, with studies estimating ranges from 5% to 70% [51].”
BackgroundTreatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181
Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.06.015 · Cited by 180
Invasive Fungal Infections in the ICU: How to Approach, How to Treat
Paramythiotou, E., Frantzeskaki, F., Flevari, A., Armaganidis, A., & Dimopoulos, G. (2014) · Molecules · doi:10.3390/molecules19011085 · Cited by 175
“Candidaemia is associated with a high mortality and increased length of hospital stay and cost [4,5].”
BackgroundGuery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1338-7 · Cited by 173
“[14] also assessed the impact of candidemia on hospital mortality in a systematic review of seven matched cohort and case–control studies.”
BackgroundBurden of Candidemia in the United States, 2017
Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa193 · Cited by 163
Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
“5) 699 (97) 696 (97) 969 (98) 790 (98) Abnormal—not clinically significant 19 (4) 0 16 (3) 5 (1) 18 (3) 21 (3) 24 (3) 21 (2) 20 (3)”
BackgroundNosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis
Pfaller, M. A., & Castanheira, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv076 · Cited by 161
“Data from these studies suggest that candidiasis is associated with substantial excess (attributable) mortality ranging from 10% to 49%[42].”
BackgroundWu, Y., Du, S., Johnson, J. L., Tung, H.-Y., Landers, C. T., Liu, Y., Seman, B. G., Wheeler, R. T., Costa-Mattioli, M., Kheradmand, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07991-4 · Cited by 143
Tortorano, A. M., Dho, G., Prigitano, A., Breda, G., Grancini, A., Emmi, V., Cavanna, C., Marino, G., Morero, S., Ossi, C., et al. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02044.x · Cited by 140
Secular trends in candidemia-related hospitalization in the United States, 2000–2005
Zilberberg, M. D., Shorr, A. F., & Kollef, M. H. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591033 · Cited by 137
(1,3)- -D-Glucan as a Prognostic Marker of Treatment Response in Invasive Candidiasis
Jaijakul, S., Vazquez, J. A., Swanson, R. N., & Ostrosky-Zeichner, L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis456 · Cited by 134
Alam, F. F., Mustafa, A. S., & Khan, Z. U. (2007) · BMC Infectious Diseases · doi:10.1186/1471-2334-7-103 · Cited by 130
“Background Candidemia is a major infectious and steadily increasing complication of seriously immunocompromised patients that is associated with high mortality rates [1-5].”
BackgroundChandra, J., McCormick, T. S., Imamura, Y., Mukherjee, P. K., & Ghannoum, M. A. (2007) · Infection and Immunity · doi:10.1128/iai.01841-06 · Cited by 130
“Candida species have emerged as the fourth most common cause of nosocomial bloodstream infections (50), with a significantly high attributable mortality (49% to 71%) ( 14 , 15).”
BackgroundRisk Factors for Fluconazole-Resistant Candidemia
Garnacho-Montero, J., Díaz-Martín, A., García-Cabrera, E., Ruiz Pérez de Pipaón, M., Hernández-Caballero, C., Aznar-Martín, J., Cisneros, J. M., & Ortiz-Leyba, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00479-10 · Cited by 127
“812 Median (p25, p75) LOS (days) before candidemia 21 (11, 35) 17 (6, 32) 0.”
BackgroundXiao, M., Fan, X., Chen, S. C.-A., Wang, H., Sun, Z.-Y., Liao, K., Chen, S.-L., Yan, Y., Kang, M., Hu, Z.-D., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku460 · Cited by 122
Hanson, K. E., Pfeiffer, C. D., Lease, E. D., Balch, A. H., Zaas, A. K., Perfect, J. R., & Alexander, B. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042282 · Cited by 122
“Invasive candidiasis (IC) is associated with high mortality, prolonged hospitalization and excess costs [1,2,3].”
BackgroundPfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.08.013 · Cited by 131
Wang, H., Xiao, M., Chen, S. C.-A., Kong, F., Sun, Z.-Y., Liao, K., Lu, J., Shao, H.-F., Yan, Y., Fan, H., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01130-12 · Cited by 105
Antifungal Quinoline Alkaloids from Waltheria indica
Cretton, S., Dorsaz, S., Azzollini, A., Favre-Godal, Q., Marcourt, L., Ebrahimi, S. N., Voinesco, F., Michellod, E., Sanglard, D., Gindro, K., et al. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00896 · Cited by 112
León, C., Ostrosky-Zeichner, L. L., & Schuster, M. G. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3281-0 · Cited by 118
Pinhati, H. M. S., Casulari, L. A., Souza, A. C. R., Siqueira, R. A., Damasceno, C. M. G., & Colombo, A. L. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1767-9 · Cited by 102
“Hospital-acquired candidemia is associated with a large increase in hospitalization duration, attributable mortality (up to 40 %) and costs [8, 9].”
BackgroundTreatment of invasive candidiasis in the elderly: a review
Dimοpoulos, G., Flevari, A., Θεοδωρακοπούλου, Μ., VELEGRAKI, & Armaganidis (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s39120 · Cited by 137
“Moreover, patients are often under fluconazole prophylaxis which may render the cultures negative at time of testing.(56) Two antigen based tests are currently available for the early diagnosis of candidemia, relying on detecting components of the fungal cell wall.”
Pendharkar, S., Brandsborg, E., Hammarström, L., Marcotte, H., & Larsson, P.-G. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0971-3 · Cited by 96
“The few clinical studies performed to date regarding supplementation of lactobacilli after conventional antifungal treatment in women with VVC show conflicting results and it is still controversial whether probiotics can prevent recurrences of VVC [19, 30, 44, 45].”
BackgroundMoran, C., Grussemeyer, C. A., Spalding, J. R., Benjamin, D. K., & Reed, S. D. (2010) · American Journal of Infection Control · doi:10.1016/j.ajic.2009.06.014 · Cited by 91
Chhablani, J. K. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.139 · Cited by 96
Lee, E. K. S., Gillrie, M. R., Li, L., Arnason, J. W., Kim, J. H., Babes, L., Lou, Y., Sanati-Nezhad, A., Kyei, S. K., Kelly, M. M., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.11.009 · Cited by 89
Paiva, J.-A., Pereira, J. M., Tabah, A., Mikstacki, A., de Carvalho, F. B., Koulenti, D., Ruckly, S., Çakar, N., Misset, B., Dimopoulos, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1229-1 · Cited by 84
“Candidemia is a severe disease linked to significant morbidity and mortality [3, 12, 13] ranging from 35–75 % [14, 15].”
BackgroundAzole Resistance in Candida glabrata
Whaley, S. G., & Rogers, P. D. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0554-5 · Cited by 85
Morbidity and Mortality of Bloodstream Infections in Patients With Severe Burn Injury
Brusselaers, N., Monstrey, S., Snoeij, T., Vandijck, D. M., Lizy, C., Hoste, E. A. J., Lauwaert, S., Colpaert, K. E., Vandekerckhove, L., Vogelaers, D., et al. (2010) · American Journal of Critical Care · doi:10.4037/ajcc2010341 · Cited by 85
Bhattacharjee, P. (2016) · Current Medical Mycology · doi:10.18869/acadpub.cmm.2.2.5 · Cited by 121
Current Options in Antifungal Pharmacotherapy
Mohr, J., Johnson, M., Cooper, T., Lewis, J. S., & Ostrosky‐Zeichner, L. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.614 · Cited by 84
Gerami-Nejad, M., Zacchi, L. F., McClellan, M., Matter, K., & Berman, J. (2013) · Microbiology · doi:10.1099/mic.0.064097-0 · Cited by 84
“albicans to reach the bloodstream, leading to systemic infections that are associated with high mortality rates (values range from ~10–15 % to ~40 % mortality due to candidaemia in the USA) (Falagas et al., 2006; Gudlaugsson et al., 2003; Zaoutis et al., 2005).”
BackgroundStrategies to Prevent Transmission of Candida auris in Healthcare Settings
Ahmad, S., & Asadzadeh, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00451-7 · Cited by 77
Excess mortality, length of stay and cost attributable to candidaemia
Hassan, I., Powell, G., Sidhu, M., Hart, W. M., & Denning, D. W. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.08.020 · Cited by 88
The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future
Tso, G. H. W., Reales-Calderon, J. A., & Pavelka, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00897 · Cited by 78
“While this figure has remained largely unchanged, the relative ranking between these species has seen significant shifts in different regions over the past decades (100).”
BackgroundChen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Pharmacokinetics of caspofungin in ICU patients
Muilwijk, E. W., Schouten, J. A., van Leeuwen, H. J., van Zanten, A. R. H., de Lange, D. W., Colbers, A. P. H., Verweij, P. E., Burger, D. M., Pickkers, P., & Brüggemann, R. J. M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku313 · Cited by 72
Yang, Z.-T., Wu, L., Liu, X.-Y., Zhou, M., Li, J., Wu, J.-Y., Cai, Y., Mao, E.-Q., Chen, E.-Z., & Lortholary, O. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-241 · Cited by 71
“as 50-70% [12,18,19].”
Antifungal Application of Nonantifungal Drugs
Stylianou, M., Kulesskiy, E., Lopes, J. P., Granlund, M., Wennerberg, K., & Urban, C. F. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01087-13 · Cited by 71
Moran, C., Grussemeyer, C. A., Spalding, J. R., Benjamin, D. K., & Reed, S. D. (2009) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181920ffd · Cited by 70
“Candida bloodstream infections are associated with significant hospital costs.(1,5) A 1997 analysis estimated the cost of candidemia in adults to be approximately $34,000 to $45,000.”
BackgroundOlaechea, P., Palomar, M., Álvarez-Lerma, F., Otal, J. J., Insausti, J., & López-Pueyo, M. J. (2013) · PubMed · Cited by 88
Management of candidiasis in the intensive care unit
Schelenz, S. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm430 · Cited by 69
Cation Transporters of Candida albicans—New Targets to Fight Candidiasis?
Volkova, M. B., Atamas, A., Tsarenko, A., Rogachev, A. V., & Guskov, A. (2021) · Biomolecules · doi:10.3390/biom11040584 · Cited by 69
“It is ranked the third most causative agent of sepsis in the United States, with about 24 cases per 100,000 patients and a mortality rate of over 40% [8,9].”
BackgroundAdhikary, R., & Joshi, S. (2011) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.83920 · Cited by 68
González de Molina, F. J., León, C., Ruiz-Santana, S., Saavedra, P., & the CAVA I Study Group (2012) · Critical Care · doi:10.1186/cc11388 · Cited by 66
“For this reason, analysis in matched cohort samples is recommended, although only seven studies assessing attributable mortality of candidemia have been previously published [23].”
Resistance of Candida albicans Biofilms to Drugs and the Host Immune System
Sandai, D. A., Tabana, Y., Ouweini, A. E., & Ishola, O. A. (2016) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.37385 · Cited by 77
“tropicalis, were also found to have generally increased in the recent years (1, 5-8).”
BackgroundLepak, A. J., Marchillo, K., VanHecker, J., Diekema, D., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01354-13 · Cited by 65
Candidemia in the Intensive Care Unit
Epelbaum, O., & Chasan, R. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.04.010 · Cited by 78
Ağbaht, K., Altıntaş, N. D., Topeli̇, A., Özkaya, Ö., & Ozcebe, O. I. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01282.x · Cited by 63
“These observations may suggest earlier start of antifungal therapy in this particular subset of patients, because candidemia itself has attributable mortality.(27) It can be speculated that impaired integrity of the intestinal mucosa in TA-GVHD may lead to translocation of yeast and this may cause candidemia.”
BackgroundShorr, A. F., Gupta, V., Sun, X., Johannes, R. S., Spalding, J., & Tabak, Y. P. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a0f95d · Cited by 62
“Attributable mortality ranged from 5% to 71% in a recent systematic review of cohort and case-control studies (7) and has not improved over time (8, 9).”
BackgroundAl-Dorzi, H. M., Sakkijha, H., Khan, R., Aldabbagh, T., Toledo, A., Ntinika, P., Al Johani, S. M., & Arabi, Y. M. (2020) · Journal of Intensive Care Medicine · doi:10.1177/0885066618767835 · Cited by 61
“A systematic review of 7 matched cohort and case-control studies found that the mortality attributed to candidemia ranged from 5% to 71%.(13) Factors that influence outcomes may include the virulence of the infecting organism, severity of the underlying illness, and the appropriateness and timing of antifungal treatme…”
BackgroundFortun, J., Meije, Y., Buitrago, M. J., Gago, S., Bernal-Martinez, L., Peman, J., Perez, M., Gomez-G Pedrosa, E., Madrid, N., Pintado, V., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku225 · Cited by 61
Secondary bile acids inhibit Candida albicans growth and morphogenesis
Guinan, J., Villa, P., & Thangamani, S. (2018) · Pathogens and Disease · doi:10.1093/femspd/fty038 · Cited by 61
Current diagnostic approaches to invasive candidiasis in critical care settings
Pemán, J., & Zaragoza, R. (2010) · Mycoses · doi:10.1111/j.1439-0507.2009.01732.x · Cited by 69
Aittakorpi, A., Kuusela, P., Koukila-Kähkölä, P., Vaara, M., Petrou, M. A., Gant, V. A., & Mäki, M. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01461-12 · Cited by 62
Del Bono, V., Delfino, E., Furfaro, E., Mikulska, M., Nicco, E., Bruzzi, P., Mularoni, A., Bassetti, M., & Viscoli, C. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05408-11 · Cited by 58
“Candida has been reported to be one of the most frequent cause of associated bloodstream infections in different health care settings (16, 26, 28) and carries an attributable mortality ranging from 5 to 71% (8).”
BackgroundInvasive candidiasis in pediatric intensive care units
Singhi, S. C., & Deep, A. (2009) · The Indian Journal of Pediatrics · doi:10.1007/s12098-009-0219-6 · Cited by 62
Ghannoum, M. A., Chen, A. W., Buhari, M. A., Chandra, J., Mukherjee, P. K., Baxa, D. M., Golembieski, A., & Vázquez, J. A. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02660.x · Cited by 57
“Approximately half of the cases of candidaemia are due to non-albicans species, such as Candida glabrata, Candida parapsilosis and Candida tropicalis [1–3].”
BackgroundCandida Peritonitis: An Update on the Latest Research and Treatments
Carneiro, H. A., Mavrakis, A., & Mylonakis, E. E. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1305-2 · Cited by 62
Amorim-Vaz, S., Delarze, E., Ischer, F., Sanglard, D., & Coste, A. T. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00367 · Cited by 64
“These larvae have been increasingly used to study fungal virulence and antifungal drug activity (Brennan et al., 2002; Mylonakis et al., 2005; Coleman et al., 2011; Thomaz et al., 2013; Favre-Godal et al., 2014).”
BackgroundInvasive Fungal Infections in the ICU
Shoham, S., & Marwaha, S. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609355262 · Cited by 63
Pitarch, A., Nombela, C., & Gil, C. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.004010 · Cited by 51
“Its significant impact on patient clinical outcome, as reflected in its increased attributable mortality (10%–49%), length of hospital stay (3–30 days per patient), and healthcare costs (US $ 6214–92,266 per episode), could however be ameliorated if early and appropriate antifungal therapeutic strategies were administ…”
BackgroundHegazi, M., Abdelkader, A., Zaki, M., & El-Deek, B. (2014) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.4186 · Cited by 50
“This was a relatively higher incidence rate of candidemia compared to a rate of 10-15% reported in other studies [20].”
ResultCandida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance
Kotey, F. C. N., Dayie, N. T. K. D., Tetteh‐Quarcoo, P. B., & Donkor, E. S. (2021) · Infectious Diseases Research and Treatment · doi:10.1177/11786337211026927 · Cited by 77
Bolous, M., Arumugam, N., Almansour, A. I., Kumar, R. S., Maruoka, K., Antharam, V. C., & Thangamani, S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.07.022 · Cited by 49
Pinto, A. P., Rosseti, I. B., Carvalho, M. L., da Silva, B. G. M., Alberto-Silva, C., & Costa, M. S. (2017) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2017.12.001 · Cited by 49
Management of Antimicrobial Use in the Intensive Care Unit
Álvarez-Lerma, F., & Grau, S. (2012) · Drugs · doi:10.2165/11599520-000000000-00000 · Cited by 52
Is Candida really a threat in the ICU?
Blot, S. I., Dimopoulos, G., Rello, J., & Vogelaers, D. (2008) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32830f1dff · Cited by 49
Diagnosis of bacteraemia and growth times
Ruiz‐Giardín, J. M., Martin-Diaz, R. M., Aroca, J. J., García-Arata, I., Martín, J. S., & Buitrago, M. S.-S. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.10.008 · Cited by 51
Impact of special patient populations on the pharmacokinetics of echinocandins
Muilwijk, E. W., Lempers, V. J. C., Burger, D. M., Warris, A., Pickkers, P., Aarnoutse, R. E., & Brüggemann, R. J. M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1028366 · Cited by 49
“Invasive candidiasis contributes highly to morbidity and mortality in these patient populations [3,4].”
BackgroundHow to Identify Invasive Candidemia in ICU—A Narrative Review
Alves, J., Alonso-Tarrés, C., & Rello, J. (2022) · Antibiotics · doi:10.3390/antibiotics11121804 · Cited by 49
“Crude mortality can reach up to 50% [5,6,8,9].”
BackgroundCandidemia on presentation to the hospital: development and validation of a risk score
Shorr, A. F., Tabak, Y. P., Johannes, R. S., Sun, X., Spalding, J., & Kollef, M. H. (2009) · Critical Care · doi:10.1186/cc8110 · Cited by 43
“More importantly, candidemia results in substantial morbidity [4-8] and mortality [7-10], especially if initial antifungal therapy is delayed or is not appropriate [5,11,12].”
BackgroundProphylaxis, empirical and preemptive treatment of invasive candidiasis
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e10e8 · Cited by 41
Zhang, X.-B., Yu, S.-J., Yu, J.-X., Gong, Y.-L., Feng, W., & Sun, F.-J. (2012) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.65.510 · Cited by 41
“Although many medical interventions and novel antifungal drugs have been developed, morbidity and mortality rates due to candidemia have hardly improved over the past 20 years (13,14).”
BackgroundKumar, A., Zarychanski, R., Pisipati, A., Kumar, A., Kethireddy, S., & Bow, E. J. (2018) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2017.1421592 · Cited by 47
“While available data suggests a significant attributable mortality with candidemia (Falagas et al. 2006) (and presumably, other forms of invasive candidiasis), our analysis is unable to definitively differentiate between the two possibilities.”
Zaragoza, R., Perman, J., Salavert, M., Viudes, Solé, A., Jarque, I., Cantón, R., Monte‐Boquet, E., & Romá, E. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3994 · Cited by 47
“A review of matched cohort and case-control studies has examined the mortality rate that could be linked to candidemia (Falagas et al 2006).”
Vardakas, K. Z., Michalopoulos, A. S., Kiriakidou, K. G., Siampli, E. P., Samonis, G., & Falagas, M. E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02653.x · Cited by 47
“Candidiasis is associated with increased overall and attributable mortality and morbidity, longer duration of ICU stay, and increased costs [5,6].”
BackgroundSelf-citationBerdal, J., Haagensen, R., Ranheim, T. E., & Bjørnholt, J. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103916 · Cited by 46
“Mortality associated with candidemias has been reported in the 40–70% range across a number of studies [6–8].”
BackgroundPérez‐Parra, A., Muñóz, P., Guinea, J., Martín‐Rabadán, P., Guembe, M., & Bouza, E. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1431-6 · Cited by 43
Benzimidazole tethered pyrrolo[3,4-b]quinoline with broad-spectrum activity against fungal pathogens
Villa, P., Arumugam, N., Almansour, A. I., Kumar, R. S., Mahalingam, S. M., Maruoka, K., & Thangamani, S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.01.006 · Cited by 38
Walker, B. S., Powers‐Fletcher, M. V., Schmidt, R. L., & Hanson, K. E. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02971-15 · Cited by 40
Epidemiology of Candida isolates from Intensive Care Units in Colombia from 2010 to 2013
Motoa, G., Muñoz, J. S., Oñate, J., Pallares, C., Hernández, C., & Villegas, M. V. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.02.006 · Cited by 45
Personalized machine learning approach to predict candidemia in medical wards
Ripoli, A., Sozio, E., Sbrana, F., Bertolino, G., Pallotto, C., Cardinali, G., Meini, S., Pieralli, F., Azzini, A. M., Concia, E., et al. (2020) · Infection · doi:10.1007/s15010-020-01488-3 · Cited by 38
Leelahavanichkul, A., Somparn, P., Bootprapan, T., Tu, H., Tangtanatakul, P., Nuengjumnong, R., Worasilchai, N., Tiranathanagul, K., Eiam‐Ong, S., Levine, M., et al. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00238.2014 · Cited by 37
“The mortality rate of patients with postsepsis systemic candidiasis is more than 50%, with more than 25% of cases of candidiasis occurring in patients who had developed sepsis (17, 22).”
Alvarez-Rueda, N., Fleury, A., Morio, F., Pagniez, F., Gastinel, L., & Le Pape, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021239 · Cited by 34
“albicans is associated with a high mortality rate and the obvious economic consequences [2,3].”
BackgroundPieralli, F., Corbo, L., Torrigiani, A., Mannini, D., Antonielli, E., Mancini, A., Corradi, F., Arena, F., Pignone, A. M., Morettini, A., et al. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1627-7 · Cited by 36
The Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · Candida and Candidiasis · doi:10.1128/9781555817176.ch29 · Cited by 33
Leonel, L. D. C., Carvalho, M. L., da Silva, B. G. M., Zamunér, S. R., Alberto-Silva, C., & Costa, M. S. (2019) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2019.04.026 · Cited by 36
Metadata
- Authors
- Falagas, M. E., Apostolou, K. E., & Pappas, V. D.
- Affiliations
- Tufts University (US)
- Alfa Institute of Biomedical Sciences (GR)
- Corresponding author
- Falagas, M. E.
- ORCID
- Falagas, M. E.
- Venue
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2006-06-14
- Volume
- 25
- Issue
- 7
- Pages
- 419-425
- ISSN
- 0934-9723 (ISSN-L)
- 1435-4373
- OpenAlex
- W2089115810
- Semantic Scholar
- aeb27cd38dec2cc6bc8a111d9effed9e8eb45139
- Cited by
- 294
- References
- 21
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 10 · 2023: 8 · 2022: 11 · 2021: 12 · 2020: 14 · 2019: 13 · 2018: 11 · 2017: 13 · 2016: 22 · 2015: 21 · 2014: 20 · 2013: 16 · 2012: 17
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Microbiology & Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, attributable mortality, invasive fungal infections, length of hospital stay, hospital costs, intensive care unit patients, transplant recipients, comorbidities
- MeSH terms
- Adult, Candida, Candidiasis, Child, Hospitalization, Humans, Length of Stay, Cohort Studies, Case-Control Studies, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.